Steroid 5-α-reductase type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: A HuGE review

American Journal of Epidemiology

Volumn 171, Issue 1, 2010, Pages 1-13

  Li, Jun ^a,b   Coates, Ralph J ^c   Gwinn, Marta ^c   Khoury, Muin J ^c  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Epidemiology; Genetic predisposition to disease; Genetics; Meta analysis; Polymorphism, genetic; Prostatic neoplasms; SRD5a2; Testosterone 5 alpha reductase

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE 2;

ALLELE; ANDROGEN; CANCER; EPIDEMIOLOGY; GENETIC STRUCTURE; GENOTYPE; HEALTH RISK; META-ANALYSIS; METABOLISM; POLYMORPHISM; STEROID; TEMPORAL ANALYSIS;

ANDROGEN DEPRIVATION THERAPY; CANCER MORTALITY; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DNA POLYMORPHISM; GENE FREQUENCY; GENE FUNCTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; META ANALYSIS; MICROARRAY ANALYSIS; PROSTATE CANCER; REVIEW; SYSTEMATIC REVIEW;

ANDROGENS; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 72949091442     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwp318     Document Type: Review

References (78)

1. Ntais C, Polycarpou A, Ioannidis JP. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2003;12(7):618-624. (Pubitemid 36899841)
2. Giwercman YL, Abrahamsson PA, Giwercman A, et al. The 5a-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. Eur Urol. 2005;48(4): 679-685.
3. Salam MT, Ursin G, Skinner EC, et al. Associations between polymorphisms in the steroid 5-a reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol. 2005;23(4):246-253.
4. Hayes VM, Severi G, Padilla EJ, et al. 5a-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int J Cancer. 2007; 120(4):776-780.
5. Cussenot O, Azzouzi AR, Nicolaiew N, et al. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. Eur Urol. 2007;52(4):1082-1087.
6. Lindström S, Zheng SL, Wiklund F, et al. Systematic replication study of reported genetic associations in prostate cancer: strong support for genetic variation in the androgen pathway. Prostate. 2006;66(16):1729-1743.
7. Li Z, Habuchi T, Mitsumori K, et al. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J Urol. 2003;169(6):2378-2381.
8. Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet. 2007; 39(8):977-983.
9. Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007;39(5):631-637.
10. Murabito JM, Rosenberg CL, Finger D, et al. A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study [electronic article]. BMC Med Genet. 2007;8(suppl 1):S6.
11. Nam RK, Zhang WW, Loblaw DA, et al. A genome-wide association screen identifies regions on chromosomes 1q25 and 7p21 as risk loci for sporadic prostate cancer. Prostate Cancer Prostatic Dis. 2007;11(3):241-246.
12. Reichardt JK, Makridakis N, Henderson BE, et al. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 1995;55(18):3973-3975.
13. Ross RK, Pike MC, Coetzee GA, et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res. 1998;58(20):4497-4504.
14. Yong EL, Lim J, Qi W, et al. Molecular basis of androgen receptor diseases. Ann Med. 2000;32(1):15-22.
15. Dorkin TJ, Neal DE. Basic science aspects of prostate cancer. Semin Cancer Biol. 1997;8(1):21-27.
16. Stanford JL, Just JJ, Gibbs M, et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res. 1997;57(6):1194-1198.
17. Makridakis NM, Reichardt JK. Molecular epidemiology of androgen-metabolic loci in prostate cancer: predisposition and progression. J Urol. 2004;171(2):S25-S28.
18. Makridakis NM, Reichardt JK. Molecular epidemiology of hormone-metabolic loci in prostate cancer. Epidemiol Rev. 2001;23(1):24-29.
19. Brawley OW, Ford LG, Thompson I, et al. 5-a-Reductase inhibition and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev. 1994;3(2):177-182.
20. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224.
21. Roddam AW, Allen NE, Appleby P, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100(3): 170-183.
22. Shabsigh R, Crawford ED, Nehra A, et al. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res. 2009;21(1):9-23.
23. Makridakis N, Ross RK, Pike MC, et al. A prevalent missense substitution that modulates activity of prostatic steroid 5a-reductase. Cancer Res. 1997;57(6):1020-1022.
24. Makridakis N, Reichardt JK. Pharmacogenetic analysis of human steroid 5a reductase type II: comparison of finasteride and dutasteride. J Mol Endocrinol. 2005;34(3):617-623.
25. Makridakis NM, di Salle E, Reichardt JK. Biochemical and pharmacogenetic dissection of human steroid 5a-reductase type II. Pharmacogenetics. 2000;10(5):407-413.
26. Makridakis NM, Ross RK, Pike MC, et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, United States. Lancet. 1999;354(9183):975-978.
27. Kantoff PW, Febbo PG, Giovannucci E, et al. A polymorphism of the 5a-reductase gene and its association with prostate cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 1997;6(3):189-192.
28. Zeigler-Johnson CM, Walker AH, Mancke B, et al. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered. 2002;54(1): 13-21.
29. Grönberg H. Prostate cancer epidemiology. Lancet. 2003; 361(9360):859-864.
30. US Cancer Statistics Working Group. United States Cancer Statistics: 2004 Incidence and Mortality. Atlanta, GA, and Bethesda, MD: Centers for Disease Control and Prevention and National Cancer Institute, 2007.
31. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94(13): 981-990.
32. Frankel S, Smith GD, Donovan J, et al. Screening for prostate cancer. Lancet. 2003;361(9363):1122-1128.
33. Dong JT. Prevalent mutations in prostate cancer. J Cell Bio-chem. 2006;97(3):433-447.
34. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med. 2008;358(9):910-919.
35. Gudmundsson J, Sulem P, Rafnar T, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet. 2008;40(3):281-283. (Pubitemid 351311771)
36. Camp NJ, Farnham JM, Wong J, et al. Replication of the 10q11 and Xp11 prostate cancer risk variants: results from a Utah pedigree-based study. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1290-1294.
37. Berndt SI, Dodson JL, Huang WY, et al. A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. J Urol. 2006;175(5):1613-1623.
38. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
39. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd ed. London, United Kingdom: BMJ Books; 2005:285-312.
40. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4): 1088-1101.
41. Stanford JL, Stephenosom RA, Coyle LM, et al. Prostate Cancer Trends, 1973-1995. Bethesda, MD: National Cancer Institute; 1999. (NIH publication no. 99-4543).
42. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990;11(2):116-128.
43. Pearce CL, Makridakis NM, Ross RK, et al. Steroid 5-a reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study. Cancer Epidemiol Biomarkers Prev. 2002;11(4):417-418.
44. Nam RK, Toi A, Vesprini D, et al. V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology. 2001;57(1): 199-204.
45. Nam RK, Zhang WW, Trachtenberg J, et al. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(12):1429-1437.
46. Lindström S, Wiklund F, Adami HO, et al. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-a-reductase type 2 is important for prostate cancer development. Cancer Res. 2006; 66(22):11077-11083.
47. Pearce CL, Van Den Berg DJ, Makridakis N, et al. No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned. Hum Mol Genet. 2008; 17(16):2456-2461.
48. Lunn RM, Bell DA, Mohler JL, et al. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reduc-tase (SRD5A2). Carcinogenesis. 1999;20(9):1727-1731.
49. Yamada Y, Watanabe M, Murata M, et al. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5a-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer. 2001; 92(5):683-686.
50. Neslund-Dudas C, Bock CH, Monaghan K, et al. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. Prostate. 2007;67(15):1654-1663.
51. Hsing AW, Chen C, Chokkalingam AP, et al. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Bio-markers Prev. 2001;10(10):1077-1082.
52. Berndt SI, Chatterjee N, Huang WY, et al. Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(1):165-168.
53. Onen IH, Ekmekci A, Eroglu M, et al. The association of 5a-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population. DNA Cell Biol. 2007;26(2):100-107.
54. Margiotti K, Sangiuolo F, De Luca A, et al. Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients. Dis Markers. 2000;16(3-4):147-150.
55. Mononen N, Ikonen T, Syrjäkoski K, et al. A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br J Cancer. 2001;84(10):1344-1347.
56. Cunningham JM, Hebbring SJ, McDonnell SK, et al. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(5):969-978.
57. Söderström T, Wadelius M, Andersson SO, et al. 5a-Reductase 2 polymorphisms as risk factors in prostate cancer. Pharma-cogenetics. 2002;12(4):307-312.
58. Febbo PG, Kantoff PW, Platz EA, et al. The V89L polymorphism in the 5a-reductase type 2 gene and risk of prostate cancer. Cancer Res. 1999;59(23):5878-5881.
59. Latil AG, Azzouzi R, Cancel GS, et al. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer. 2001;92(5):1130-1137.
60. Lamharzi N, Johnson MM, Goodman G, et al. Polymorphic markers in the 5a-reductase type II gene and the incidence of prostate cancer. Int J Cancer. 2003;105(4):480-483.
61. Chang BL, Zheng SL, Isaacs SD, et al. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer. Prostate. 2003;56(1):37-44.
62. Sobti RC, Onsory K, Al-Badran AI, et al. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol. 2006; 25(5):287-294.
63. Pompanon F, Bonin A, Bellemain E, et al. Genotyping errors: causes, consequences and solutions. Nat Rev Genet. 2005; 6(11):847-859.
64. Verzilli CJ, Stallard N, Whittaker JC. Bayesian graphical models for genomewide association studies. Am J Hum Genet. 2006;79(1):100-112.
65. Allen NE, Forrest MS, Key TJ. The association between polymorphisms in the CYP17 and 5a-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol Biomarkers Prev. 2001;10(3):185-189.
66. Allen NE, Reichardt JK, Nguyen H, et al. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men. Cancer Epidemiol Biomarkers Prev. 2003;12(6):578-581.
67. Granfors T, Modig H, Damber JE, et al. Combined orchiec-tomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol. 1998;159(6):2030-2034.
68. Schmidt JD, Gibbons RP, Murphy GP, et al. Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project. Prostate. 1996;28(1):51-57.
69. Vastag B. Preventing prostate cancer: new analyses put finas-teride back on the map. J Natl Cancer Inst. 2008;100(16): 1132-1133.
70. Gorlov IP, Gallick GE, Gorlova OY, et al. GWAS meets mi-croarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example [electronic article]. PLoS One. 2009;4(8):e6511.
71. Ioannidis JP, Boffetta P, Little J, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol. 2008;37(1):120-132.
72. Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet. 2006;7(10):781-791.
73. Brawley OW, Ankerst DP, Thompson IM. Screening for prostate cancer. CA Cancer J Clin. 2009;59(4):264-273.
74. Cicek MS, Conti DV, Curran A, et al. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate. 2004;59(1):69-76.
75. Forrest MS, Edwards SM, Houlston R, et al. Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer Prostatic Dis. 2005;8(1): 95-102.
76. Marcelli M, Cunningham GR. Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab. 1999; 84(10):3463-3468.
77. Schatzl G, Madersbacher S, Gsur A, et al. Association of polymorphisms within androgen receptor, 5a-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. Prostate. 2002;52(2): 130-138.
78. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8(4):268-278.